Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

Portola Pharmaceuticals Company Profile (NASDAQ:PTLA)

Consensus Ratings for Portola Pharmaceuticals (NASDAQ:PTLA) (?)
Ratings Breakdown: 1 Hold Rating(s)
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $41.85 (11.75% upside)

Analysts' Ratings History for Portola Pharmaceuticals (NASDAQ:PTLA)
Show:
DateFirmActionRatingPrice TargetDetailsShare
3/17/2015Credit Suisse Group AGBoost Price Target$51.00ViewTweet This Rating  Share This Rating on StockTwits
1/2/2015ZacksDowngradeOutperform -> Neutral$32.70ViewTweet This Rating  Share This Rating on StockTwits
10/7/2014ZacksDowngradeOutperform -> Neutral$31.10ViewTweet This Rating  Share This Rating on StockTwits
8/12/2014ZacksUpgradeNeutral -> Outperform$28.30ViewTweet This Rating  Share This Rating on StockTwits
11/6/2013Cowen and CompanyLower Price TargetOutperform$47.00 -> $45.00ViewTweet This Rating  Share This Rating on StockTwits
8/16/2013Cowen and CompanyBoost Price TargetOutperform$45.37 -> $47.00ViewTweet This Rating  Share This Rating on StockTwits
6/27/2013Sanford C. BernsteinInitiated CoverageOutperformViewTweet This Rating  Share This Rating on StockTwits
6/20/2013Cowen and CompanyInitiated CoverageOutperform$45.00ViewTweet This Rating  Share This Rating on StockTwits
6/17/2013Credit Suisse Group AGReiterated RatingOutperform$30.00 -> $30.00ViewTweet This Rating  Share This Rating on StockTwits
6/17/2013William BlairReiterated RatingOutperformViewTweet This Rating  Share This Rating on StockTwits
6/17/2013Morgan StanleyReiterated RatingOverweightViewTweet This Rating  Share This Rating on StockTwits
(Data available from 5/4/2013 forward)